Access to innovation: is there a difference in the use of expensive anticancer drugs between French hospitals?

摘要: Abstract In DRG-based hospital payment systems, expensive drugs are often funded separately. France, specific (including a large proportion of anticancer drugs) fully reimbursed up to national reimbursement tariffs ensure equity access. Our objective was analyse the use in public and private hospitals, between regions. We had access sales per drug year 2008. used multilevel model study variation mean expenditure course chemotherapy hospital. The € 922 [95% CI: 890–954]. At level, specialisation chemotherapies for breast cancers associated with higher those hospitals highest at this site. There were no differences sector after controlling case mix. expenditures region. absence disparities regions may indicate that exempting from payments providing additional these has been successful ensuring equal care.